Cargando…

Younger age and female gender are determinants of underestimated cardiovascular risk in rheumatoid arthritis patients: a prospective cohort study

BACKGROUND: Rheumatoid arthritis (RA) patients have an increased cardiovascular (CV) risk. Here, we aimed to investigate whether gender and age are contributing to the misclassification of CV risk in RA patients. METHODS: Prospectively collected data on cardiovascular risk factors and incident event...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rohrich, Daphne C., van de Wetering, Eline H. M., Rennings, Alexander J., Arts, Elke E., Meek, Inger L., den Broeder, Alfons A., Fransen, Jaap, Popa, Calin D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784252/ https://www.ncbi.nlm.nih.gov/pubmed/33397472 http://dx.doi.org/10.1186/s13075-020-02384-9

Ejemplares similares

Rheumatoid Arthritis Disadvantages Younger Patients for Cardiovascular Diseases: A Meta-Analysis
por: Fransen, Jaap, et al.
Publicado: (2016)

Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals
por: Popa, Calin D., et al.
Publicado: (2012)

High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study
por: Arts, Elke, et al.
Publicado: (2012)

Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial
por: den Broeder, Alfons A., et al.
Publicado: (2017)

(Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challenges
por: den Broeder, Alfons A, et al.
Publicado: (2021)

Angiotensin-Inhibiting Drugs Do Not Impact Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Cross-Sectional Study
por: Sluijsmans, Dorien M. C. F., et al.
Publicado: (2021)

Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients
por: Damen, Michelle S. M. A., et al.
Publicado: (2018)

Efficacy of a Web-Based Self-Management Enhancing Program for Patients with Rheumatoid Arthritis: Explorative Randomized Controlled Trial
por: Zuidema, Rixt, et al.
Publicado: (2019)

Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry
por: Vermeer, Marloes, et al.
Publicado: (2013)

Serum Samples That Have Been Stored Long-Term (>10 Years) Can Be Used as a Suitable Data Source for Developing Cardiovascular Risk Prediction Models in Large Observational Rheumatoid Arthritis Cohorts
por: Arts, Elke E. A., et al.
Publicado: (2014)

The epigenome of synovial fibroblasts: an underestimated therapeutic target in rheumatoid arthritis
por: Frank-Bertoncelj, Mojca, et al.
Publicado: (2014)

Atherosclerosis in Rheumatoid Arthritis
por: González-Gay, Miguel A., et al.
Publicado: (2012)

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)
por: van der Togt, Céleste J.T., et al.
Publicado: (2022)

DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis
por: van Riel, Piet LCM, et al.
Publicado: (2005)

Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature
por: Meek, Inger L, et al.
Publicado: (2014)

Extra-articular findings with FDG-PET/CT in rheumatoid arthritis patients: more harm than benefit
por: Ulijn, Evy, et al.
Publicado: (2022)

bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search
por: Verhoef, Lise M., et al.
Publicado: (2017)

Time to achieve remission determines time to be in remission
por: Schipper, Lydia G, et al.
Publicado: (2010)

Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis
por: van der Togt, Céleste J T, et al.
Publicado: (2022)

SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis
por: Gómez-Vaquero, Carmen, et al.
Publicado: (2013)

Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis
por: van der Togt, Céleste J T, et al.
Publicado: (2022)

Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis
por: Zwikker, Hanneke E, et al.
Publicado: (2014)

Enhanced Cardiovascular Risk in Rheumatoid Arthritis: Elucidation, Assessment, and Management
por: Dessein, Patrick H., et al.
Publicado: (2015)

IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis
por: Damen, Michelle S. M. A., et al.
Publicado: (2017)

Fatigue – an underestimated symptom in psoriatic arthritis
por: Krajewska-Włodarczyk, Magdalena, et al.
Publicado: (2017)

Comparison of Biologic Discontinuation in Patients With Elderly‐Onset Versus Younger‐Onset Rheumatoid Arthritis
por: Richter, Michael D., et al.
Publicado: (2019)

Abatacept and tocilizumab tapering in rheumatoid arthritis patients: results of SONATA—a retrospective, exploratory cohort study
por: Bouman, Chantal A M, et al.
Publicado: (2018)

Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis
por: Hendrikx, Jos, et al.
Publicado: (2016)

Smoking–gender interaction and risk for rheumatoid arthritis
por: Krishnan, Eswar, et al.
Publicado: (2003)

Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review
por: Wientjes, Maike H M, et al.
Publicado: (2022)

Monitoring rheumatoid arthritis using an algorithm based on patient-reported outcome measures: a first step towards personalised healthcare
por: Hendrikx, Jos, et al.
Publicado: (2015)

The revised Bristol Rheumatoid Arthritis Fatigue measures and the Rheumatoid Arthritis Impact of Disease scale: validation in six countries
por: Hewlett, Sarah, et al.
Publicado: (2018)

What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?
por: Bouman, Chantal A M, et al.
Publicado: (2017)

Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative
por: Li, Xiuying, et al.
Publicado: (2022)

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis
por: Tweehuysen, Lieke, et al.
Publicado: (2018)

Outcome of unlinked total elbow arthroplasty for rheumatoid arthritis in patients younger than 50 years old
por: Nishida, Keiichiro, et al.
Publicado: (2023)

Age-Related Health Hazards in Old Patients with First-Time Referral to a Rheumatologist: A Descriptive Study
por: van Lankveld, W., et al.
Publicado: (2011)

What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis
por: Messelink, Marianne A, et al.
Publicado: (2023)

Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial
por: Messelink, Marianne A., et al.
Publicado: (2022)

Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial
por: van Boheemen, Laurette, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5099ig28lok9j0753codgo8rdv